Effect of antimicrobials on Stenotrophomonas maltophilia biofilm

References

• 1. Ryan RP, Monchy S, Cardinale M et al. The versatility and adaptation of bacteria from the genus Stenotrophomonas. Nat. Rev. Microbiol. 7(7), 514–525 (2009).
  Medline CASGoogle Scholar
• 2. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol. Rev. 25(1), 2–41 (2012).
  Medline CASGoogle Scholar
• 3. Adegoke AA, Stenström TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front. Microbiol. 8(2 Suppl. 4), 627–631 (2017).
  MedlineGoogle Scholar
• 4. Lai C-H, Chi C-Y, Chen H-P et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J. Microbiol. Immunol. Infect. 37(6), 350–358 (2004).
  MedlineGoogle Scholar
• 5. Alat I, Kılıç AT, Çelik E. Replacement of the native mitral valve due to endocarditis caused by Stenotrophomonas maltophilia. Brazilian J. Cardiovasc. Surg. 34(5), 615–617 (2019).
  MedlineGoogle Scholar
• 6. Golestaneh L, Mokrzycki MH. Prevention of hemodialysis catheter infections: ointments, dressings, locks, and catheter hub devices. Hemodial. Int. 22(S2), S75–S82 (2018).
  MedlineGoogle Scholar
• 7. Roehr AC, Frey OR, Koeberer A, Fuchs T, Roberts JA, Brinkmann A. Anti-infective drugs during continuous hemodialysis – using the bench to learn what to do at the bedside. Int. J. Artif. Organs 38(1), 17–22 (2015).
  Medline CASGoogle Scholar
• 8. Thet MK, Pelobello MLF, Das M et al. Outbreak of nonfermentative Gram-negative bacteria (Ralstonia pickettii and Stenotrophomonas maltophilia) in a hemodialysis center. Hemodial. Int. 23(3), E83–E89 (2019).
  MedlineGoogle Scholar
• 9. Pompilio A, Crocetta V, De Nicola S, Verginelli F, Fiscarelli E, Di Bonaventura G. Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm. Front. Microbiol. 6, 951 (2015).
  MedlineGoogle Scholar
• 10. Díez-Aguilar M, Ekkelenkamp M, Morosini M-I et al. Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients. Int. J. Antimicrob. Agents. 53(1), 84–88 (2018).
  MedlineGoogle Scholar
• 11. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23(2), 299–323 (2010).
  MedlineGoogle Scholar
• 12. Pompilio A, Pomponio S, Crocetta V et al. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol. 11, 159 (2011).
  MedlineGoogle Scholar
• 13. Alcaraz E, Garcia C, Papalia M, Vay C, Friedman L, Passerini de Rossi B. Stenotrophomonas maltophilia isolated from patients exposed to invasive devices in a university hospital in Argentina: molecular typing, susceptibility and detection of potential virulence factors. J. Med. Microbiol. 67(7), 992–1002 (2018).
  Medline CASGoogle Scholar
• 14. Flores-Treviño S, Bocanegra-Ibarias P, Camacho-Ortiz A, Morfín-Otero R, Salazar-Sesatty HA, Garza-González E. Stenotrophomonas maltophilia biofilm: its role in infectious diseases. Expert Rev. Anti Infect. Ther. 17(11), 877–893 (2019).
  Medline CASGoogle Scholar
• 15. Flemming H-C, Wingender J. The biofilm matrix. Nat. Rev. Microbiol. 8(9), 623–633 (2010).
  Medline CASGoogle Scholar
• 16. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 358(9276), 135–138 (2001).
  Medline CASGoogle Scholar
• 17. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2(2), 95–108 (2004).
  Medline CASGoogle Scholar
• 18. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 322, 107–131 (2008).
  Medline CASGoogle Scholar
• 19. Miyaue S, Suzuki E, Komiyama Y, Kondo Y, Morikawa M, Maeda S. Bacterial memory of persisters: bacterial persister cells can retain their phenotype for days or weeks after withdrawal from colony–biofilm culture. Front. Microbiol. 9(JUN), 1396 (2018).
  MedlineGoogle Scholar
• 20. Soi V, Moore CL, Kumbar L, Yee J. Prevention of catheter-related bloodstream infections in patients on hemodialysis: challenges and management strategies. Int. J. Nephrol. Renovasc. Dis. 9, 95–103 (2016).
  MedlineGoogle Scholar
• 21. Eschenauer GA, Lam SW, Mueller BA. Dose timing of aminoglycosides in hemodialysis patients: a pharmacology view. Semin. Dial. 29(3), 204–213 (2016).
  MedlineGoogle Scholar
• 22. Pinner NA, Canada RB, Broyles JE, Hudson JQ. Evaluation of vancomycin and gentamicin dialysis clearance using in vivo and in vitro systems. Ren. Fail. 34(6), 703–707 (2012).
  Medline CASGoogle Scholar
• 23. Vitória da MP, Alvarenga de S CG, Vasconcellos Filho LM et al. Low serum trough concentrations and high vancomycin minimum inhibitory concentration in methicillin-sensitive Staphylococcus aureus From hemodialysis patients in Brazil. Ther. Drug Monit. 41(1), 38–43 (2019).
  MedlineGoogle Scholar
• 24. CLSI. Performance Standards for Antimicrobial Susceptibility Testing - CLSI supplement M100 (29th Edition). Clinical and Laboratory Standards Institute, PA, USA (2019).
  Google Scholar
• 25. Matson HH, Jones BM, Wagner JL, Motes MA, Bland CM. Growing resistance in Stenotrophomonas maltophilia? Am. J. Heal. Pharm. 76(24), 2004–2005 (2019).
  MedlineGoogle Scholar
• 26. Pompilio A, Savini V, Fiscarelli E, Gherardi G, Di Bonaventura G. Clonal diversity, biofilm formation, and antimicrobial resistance among Stenotrophomonas maltophilia strains from cystic fibrosis and non-cystic fibrosis patients. Antibiotics 9(1), 15 (2020).
  CASGoogle Scholar
• 27. Whitby PW, Carter KB, Burns JL, Royall JA, LiPuma JJ, Stull TL. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J. Clin. Microbiol. 38(12), 4305–4309 (2000).
  Medline CASGoogle Scholar
• 28. Versalovic J, Koeuth T, Lupski R. Distribution of repetitive DNA sequences in eubacteria and application to finerpriting of bacterial enomes. Nucleic Acids Res. 19(24), 6823–6831 (1991).
  Medline CASGoogle Scholar
• 29. Heras J, Domínguez C, Mata E et al. GelJ – a tool for analyzing DNA fingerprint gel images. BMC Bioinformatics 16(1), 270 (2015).
  MedlineGoogle Scholar
• 30. Stepanović S, Vuković D, Hola V et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 115(8), 891–899 (2007).
  MedlineGoogle Scholar
• 31. Wang A, Wang Q, Kudinha T, Xiao S, Zhuo C. Effects of fluoroquinolones and azithromycin on biofilm formation of Stenotrophomonas maltophilia. Sci. Rep. 6(1), 1–11 (2016).
  MedlineGoogle Scholar
• 32. Di Bonaventura G, Stepanović S, Picciani C, Pompilio A, Piccolomini R. Effect of environmental factors on biofilm formation by clinical Stenotrophomonas maltophilia isolates. Folia Microbiol. (Praha). 52(1), 86–90 (2007).
  MedlineGoogle Scholar
• 33. Pompilio A, Crocetta V, Confalone P et al. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol. 10, 102 (2010).
  MedlineGoogle Scholar
• 34. Kaur P, Gautam V, Tewari R. Distribution of Class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a Tertiary Care Hospital in North India. Microb. Drug Resist. 21(4), 380–385 (2015).
  Medline CASGoogle Scholar
• 35. Juhász E, Krizsán G, Lengyel G, Grósz G, Pongrácz J, Kristóf K. Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann. Clin. Microbiol. Antimicrob. 13(1), 333 (2014).
  MedlineGoogle Scholar
• 36. Caylan R, Kaklikkaya N, Aydin K et al. An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital. Jpn J. Infect. Dis. 57(2), 37–40 (2004).
  MedlineGoogle Scholar
• 37. Pompilio A, Crocetta V, Scocchi M et al. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol. 12, 145 (2012).
  Medline CASGoogle Scholar
• 38. Wu K, Yau YCW, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 57(3), 1546–1548 (2013).
  Medline CASGoogle Scholar
• 39. Sun E, Liang G, Wang L et al. Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms. Brazilian J. Infect. Dis. 20(4), 365–373 (2016).
  MedlineGoogle Scholar
• 40. Esposito A, Vollaro A, Esposito EP et al. Antibacterial and antivirulence activity of glucocorticoid PYED-1 against Stenotrophomonas maltophilia. Antibiotics 9(3), 105 (2020).
  CASGoogle Scholar
• 41. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb. Perspect. Med. 6(6), (2016). doi:10.1101/cshperspect.a027029
  MedlineGoogle Scholar
• 42. O'Shea S, Duffull S, Johnson DW. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? Semin. Dial. 22(3), 225–230 (2009).
  MedlineGoogle Scholar
• 43. Nicodemo AC, Araujo MRE, Ruiz AS, Gales AC. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J. Antimicrob. Chemother. 53(4), 604–608 (2004).
  Medline CASGoogle Scholar
• 44. Savini V, Catavitello C, D'Aloisio M et al. Chloramphenicol and rifampin may be the only options against Stenotrophomonas maltophilia. A tale of a colonized bladder device in a patient with myelofibrosis. Infez. Med. 18(3), 193–197 (2010).
  MedlineGoogle Scholar
• 45. Hu L-F, Xu X-H, Li H-R et al. Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005–2014. J. Chemother. 30(1), 25–30 (2018).
  MedlineGoogle Scholar
• 46. Gallo SW, Figueiredo TP, Bessa MC, Pagnussatti VE, Ferreira CAS, Oliveira SD. Isolation and characterization of Stenotrophomonas maltophilia isolates from a Brazilian Hospital. Microb. Drug Resist. 22(8), 688–695 (2016).
  Medline CASGoogle Scholar
• 47. Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and microbiologic outcomes in patients with monomicrobial Stenotrophomonas maltophilia infections. Antimicrob. Agents Chemother. 63(11), e00788–19 (2019).
  Medline CASGoogle Scholar
• 48. Grillon A, Schramm F, Kleinberg M, Jehl F. Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies. PLoS ONE 11(6), e0156690 (2016).
  MedlineGoogle Scholar
• 49. Tan R, Liu J, Li M, Huang J, Sun J, Qu H. Epidemiology and antimicrobial resistance among commonly encountered bacteria associated with infections and colonization in intensive care units in a university-affiliated hospital in Shanghai. J. Microbiol. Immunol. Infect. 47(2), 87–94 (2014).
  MedlineGoogle Scholar
• 50. Chung HS, Hong SG, Kim YR et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J. Korean Med. Sci. 28(1), 62–66 (2013).
  Medline CASGoogle Scholar
• 51. Yang Q, Wang H, Chen M et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002–2009 study for monitoring antimicrobial resistance trends (SMART). Int. J. Antimicrob. Agents. 36(6), 507–512 (2010).
  Medline CASGoogle Scholar
• 52. Pompilio A, Catavitello C, Picciani C et al. Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. J. Med. Microbiol. 59(Pt 1), 76–81 (2010).
  Medline CASGoogle Scholar
• 53. Passerini de Rossi B, García C, Calenda M, Vay C, Franco M. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections. Int. J. Antimicrob. Agents. 34(3), 260–264 (2009).
  MedlineGoogle Scholar
• 54. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997–1999). Clin. Infect. Dis. 32(s2), S104–S113 (2001).
  Medline CASGoogle Scholar
• 55. Kanderi T, Shrimanker I, Mansoora Q, Shah K, Yumen A, Komanduri S. Stenotrophomonas maltophilia: an emerging pathogen of the respiratory tract. Am. J. Case Rep. 21, e921466–1 (2020).
  MedlineGoogle Scholar
• 56. Cruz-Córdova A, Mancilla-Rojano J, Luna-Pineda VM et al. Molecular epidemiology, antibiotic resistance, and virulence traits of Stenotrophomonas maltophilia strains associated with an outbreak in a Mexican Tertiary Care Hospital. Front. Cell. Infect. Microbiol. 10 (2020).
  MedlineGoogle Scholar
• 57. Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob. Agents Chemother. 48(1), 151–160 (2004).
  MedlineGoogle Scholar
• 58. Biočanin M, Madi H, Vasiljević Z, Kojić M, Jovčić B, Lozo J. Temperature, pH and trimethoprim-sulfamethoxazole are potent inhibitors of biofilm formation by Stenotrophomonas maltophilia clinical isolates. Polish J. Microbiol. 66(4), 433–438 (2017).
  MedlineGoogle Scholar
• 59. Chang Y-T, Lin C-Y, Chen Y-H, Hsueh P-R. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front. Microbiol. 6, 893 (2015).
  MedlineGoogle Scholar
• 60. Furner-Pardoe J, Anonye BO, Cain R et al. Anti-biofilm efficacy of a medieval treatment for bacterial infection requires the combination of multiple ingredients. Sci. Rep. 10(1), 12687 (2020).
  MedlineGoogle Scholar
• 61. Kačániová M, Galovičová L, Ivanišová E et al. Antioxidant, antimicrobial and antibiofilm activity of coriander (Coriandrum sativum L.) essential oil for its application in foods. Foods 9(3), 282 (2020).
  CASGoogle Scholar